Eisai Co., Ltd. (ESALY.PK,ESALF.PK,4523.T) and Biogen Inc. (BIIB) announced that the National Medical Products Administration (NMPA) of China has approved LEQEMBI—a humanized monoclonal antibody targeting soluble aggregated amyloid-beta (Aß)—for intravenous (IV) maintenance dosing once every four weeks.
This approval supports the continued treatment of patients with early-stage Alzheimer's disease, including those with mild cognitive impairment (MCI) or mild dementia. Following an 18-month initiation phase of 10 mg/kg dosing every two weeks, patients may transition to the newly approved maintenance regimen or continue with the biweekly schedule.
In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in China.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.